Market Closed -
Nasdaq
04:00:00 2024-07-10 pm EDT
|
5-day change
|
1st Jan Change
|
3.32
USD
|
+6.07%
|
|
+7.44%
|
-10.46%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
16.14
|
55.03
|
153.2
|
70.41
|
30.46
|
27.97
|
-
|
-
|
Enterprise Value (EV)
1 |
16.14
|
55.03
|
153.2
|
70.41
|
30.46
|
27.97
|
27.97
|
27.97
|
P/E ratio
|
-0.85
x
|
-1.47
x
|
-3.17
x
|
-2.24
x
|
-0.88
x
|
-1.17
x
|
-2.44
x
|
18.4
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
7.04
x
|
10.8
x
|
10.7
x
|
1
x
|
0.51
x
|
EV / Revenue
|
-
|
-
|
-
|
7.04
x
|
10.8
x
|
10.7
x
|
1
x
|
0.51
x
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-
|
-2,179,024
x
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-0%
|
-
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
1,640
|
3,422
|
6,383
|
7,069
|
8,214
|
8,424
|
-
|
-
|
Reference price
2 |
9.840
|
16.08
|
24.00
|
9.960
|
3.708
|
3.320
|
3.320
|
3.320
|
Announcement Date
|
3/27/20
|
3/30/21
|
3/31/22
|
3/30/23
|
3/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
10
|
2.808
|
2.625
|
27.84
|
54.4
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-14.34
|
-27.4
|
-39.07
|
-31.39
|
-30.94
|
-21.72
|
-7.628
|
12.94
|
Operating Margin
|
-
|
-
|
-
|
-313.85%
|
-1,101.89%
|
-827.66%
|
-27.4%
|
23.78%
|
Earnings before Tax (EBT)
1 |
-14.26
|
-27.4
|
-38.7
|
-30.95
|
-30.16
|
-23.92
|
-9.987
|
6.934
|
Net income
1 |
-15.05
|
-27.41
|
-38.7
|
-30.95
|
-30.16
|
-23.93
|
-10.3
|
5.844
|
Net margin
|
-
|
-
|
-
|
-309.48%
|
-1,074.17%
|
-911.69%
|
-37%
|
10.74%
|
EPS
2 |
-11.64
|
-10.92
|
-7.560
|
-4.440
|
-4.200
|
-2.833
|
-1.360
|
0.1800
|
Free Cash Flow
|
-
|
-25.25
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/27/20
|
3/30/21
|
3/31/22
|
3/30/23
|
3/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
-
|
-
|
10
|
-
|
-
|
-
|
-
|
1
|
1.808
|
0.0093
|
0.1893
|
1.031
|
1.395
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-9.543
|
-8.4
|
0.3843
|
-7.139
|
-16.23
|
-8.383
|
-8.989
|
-8.396
|
-5.171
|
-6.022
|
-5.383
|
-5.57
|
-4.749
|
-
|
-
|
Operating Margin
|
-
|
-
|
3.84%
|
-
|
-
|
-
|
-
|
-839.64%
|
-286.05%
|
-64,757.74%
|
-2,843.18%
|
-540.39%
|
-340.33%
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-9.542
|
-8.399
|
0.414
|
-7.02
|
-15.94
|
-8.042
|
-8.762
|
-8.299
|
-5.058
|
-6.755
|
-5.328
|
-6.377
|
-5.506
|
-
|
-
|
Net income
1 |
-9.542
|
-8.399
|
0.414
|
-7.02
|
-15.94
|
-8.042
|
-8.762
|
-8.299
|
-5.058
|
-6.755
|
-5.328
|
-6.377
|
-5.506
|
-
|
-
|
Net margin
|
-
|
-
|
4.14%
|
-
|
-
|
-
|
-
|
-829.91%
|
-279.75%
|
-72,638.28%
|
-2,813.96%
|
-618.72%
|
-394.63%
|
-
|
-
|
EPS
2 |
-2.160
|
-1.200
|
0.0588
|
-0.9600
|
-2.280
|
-1.080
|
-1.200
|
-1.080
|
-0.7200
|
-0.8400
|
-0.6567
|
-0.7400
|
-0.6133
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/31/22
|
5/12/22
|
8/9/22
|
11/10/22
|
3/30/23
|
5/11/23
|
8/10/23
|
11/9/23
|
3/28/24
|
5/14/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-25.3
|
-
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
-
|
0.02
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/27/20
|
3/30/21
|
3/31/22
|
3/30/23
|
3/28/24
|
-
|
-
|
-
|
Last Close Price
3.32
USD Average target price
52.25
USD Spread / Average Target +1,473.80% Consensus |
1st Jan change
|
Capi.
|
---|
| -10.46% | 27.97M | | +18.09% | 45.01B | | +45.49% | 40.96B | | -8.38% | 38.62B | | +34.66% | 32.6B | | -8.34% | 27.49B | | +16.10% | 27.17B | | +49.73% | 14.61B | | +36.71% | 12.95B | | -6.60% | 11.36B |
Other Biotechnology & Medical Research
|